Key result
Endothelial microparticles were significantly elevated in peripartum cardiomyopathy compared with healthy controls and other cardiac diseases (P<0.001), and were reduced by bromocriptine.
Why the study?
Do circulating microparticle profiles distinguish peripartum cardiomyopathy from normal pregnancy and other cardiovascular diseases, and does bromocriptine treatment reduce their levels?
Population
Patients with peripartum cardiomyopathy and various control groups including age-matched healthy post-partum…
Comparison
Bromocriptine added to heart failure therapy vs Heart failure therapy alone without bromocriptine
Design
Case-control
Authors
Loading...
Endothelial microparticles may aid peripartum cardiomyopathy diagnosis; leaves open biomarker utility and bromocriptine effects pending prospective data.
Observational
Do circulating microparticle profiles distinguish peripartum cardiomyopathy from normal pregnancy and other cardiovascular diseases, and does bromocriptine treatment reduce their levels?
p-value: p=< 0.001
Circulating microparticle profiles may serve as a diagnostic biomarker to distinguish peripartum cardiomyopathy from normal pregnancy and other cardiovascular diseases, and their reduction with bromocriptine supports its pathogenetic relevance.
Walenta et al. (2012) conducted an observational in Peripartum cardiomyopathy. Peripartum cardiomyopathy vs. Healthy controls and patients with other cardiovascular diseases was evaluated on Endothelial microparticle (EMP) levels (p=< 0.001). Endothelial microparticles were significantly elevated in peripartum cardiomyopathy compared with healthy controls and other cardiac diseases (P<0.001), and were reduced by bromocriptine.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: